Alnylam Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic …
Biotechnology
US, Cambridge [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 28% Weak
Profitability n.A. n.A.
Fin. Growth 33% Weak
Leverage & Liquidity 17% Weak
Per Share Metrics 33% Weak
Fin. Health n.A. n.A.
1 Financial Health
Metric Q4 Q1 Δ in %
Current Ratio 2.97 3.17 3.08
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA -268.39 -66.93 -18.17
Naive Interpretation member
2 Per Share
Metric Q4 Q1 Δ in %
Book Value 1.04 -1.74 -1.76
Cash -3.20 18.80 19.42
Capex 15.61 -0.10 -0.12
Free Cash Flow -108.62 -0.75 -0.36
Revenue 11.95 3.92 3.50
Naive Interpretation member
3 Profitability
Metric Q4 Q1 Δ in %
Gross Margin 7.68 0.87 0.80
Operating Margin 66.81 -0.09 -0.26
ROA 52.11 -0.02 -0.04
ROE -51.88 0.30 0.62
ROIC 61.50 -0.02 -0.05
Naive Interpretation member
4 Valuation
The "Valuation Entry" for the Focus of ALNY is permitted for members.
5 Growth
The "Growth Entry" for the Focus of ALNY is permitted for members.
6 Leverage & Liquidity
The "Leverage & Liquidity Entry" for the Focus of ALNY is permitted for members.
End of ALNY's Analysis
CIK: 1178670 CUSIP: 02043Q107 ISIN: US02043Q1076 LEI: - UEI: -
Secondary Listings